Efrain Gomez

TL;DR: Angiotensin-neprilysin inhibition prevents the clinical progression of surviving patients with heart failure more effectively than angiotens in-converting enzyme inhibition.

TL;DR: There were many regional differences in PARADIGM-HF, including in age, symptoms, comorbidity, background therapy, and event-rates, although these did not modify the benefit of sacubitril/valsartan.

TL;DR: In this paper, the angiotensin receptor-neprilysin inhibitor LCZ696 was compared with enalapril in PARADIGM-HF, and the results showed that the strategy of combined renin receptor blockade and neprilysin inhibition led to striking reductions in cardiovascular and all-cause mortality, as well as heart failure hospitalization.

TL;DR: Despite younger age, less comorbidity, and comprehensive use of conventional HF therapies, patients with Chagasic HF with reduced ejection fraction continue to have worse quality of life and higher hospitalization and mortality rates compared with other etiologies.

TL;DR: Bocchi et al. as discussed by the authors performed a post hoc analysis of the SHIFT trial and found that the safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease were similar to those of the standard CT-based methods.